Table of Contents Author Guidelines Submit a Manuscript
International Journal of Breast Cancer
Volume 2014 (2014), Article ID 627352, 6 pages
http://dx.doi.org/10.1155/2014/627352
Clinical Study

Early Invasive Cancer and Partial Intraoperative Electron Radiation Therapy of the Breast: Experience of the Jules Bordet Institute

1Department of Radiation Oncology, Jules Bordet Institute, 1000 Brussels, Belgium
2Department of Radiophysics, Jules Bordet Institute, 1000 Brussels, Belgium
3Department of Surgery, Jules Bordet Institute, 1000 Brussels, Belgium
4Department of Pathology, Jules Bordet Institute, 1000 Brussels, Belgium
5Department of Nuclear Medicine, Jules Bordet Institute, 1000 Brussels, Belgium

Received 14 February 2014; Revised 26 April 2014; Accepted 12 May 2014; Published 9 June 2014

Academic Editor: Felix Sedlmayer

Copyright © 2014 C. Philippson et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objectives. The aim of this prospective phase II study is to evaluate the treatment of early-stage breast cancer (T1 N0) with intraoperative electron radiation therapy (IOERT) in terms of local control, early complications, and cosmesis. Patients and Methods. From February 2010 to February 2012, 200 patients underwent partial IOERT of the breast. Inclusion criteria were unifocal invasive ductal carcinoma, age ≥40 years, histological tumour size ≤20 mm, and no lymph node involvement. A 21 Gy dose was prescribed over the 90% isodose line in the tumour bed. Median follow-up is 23.3 months (7–37). Results. Acute toxicity was not frequent (Grade 1: 4.5%, Grade 2: 1%). The cosmetic result was considered to be very good or good in 92.5%. One ipsi lateral out-quadrant recurrence at 18 months was observed. The crude and actuarial local recurrence rates after median follow-up were 0.5% and 0.9%, respectively. Conclusion. The preoperative diagnostic work-up must be comprehensive and the selection process must be rigorous for this therapeutic approach reserved for small ductal unifocal cancers. After a 23.3-month median follow-up time, the clinical results of IOERT for selected patients are encouraging for the locoregional recurrence and the toxicity rates. The satisfaction of our patients in terms of quality of life was extremely high.